1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,440 | 1,550 | 11:44 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Q-LINEA Aktie jetzt für 0€ handeln | |||||
| 20.08. | Q-Linea AB: Q-linea appoints Malin Svensson as new Chief Financial Officer | 589 | GlobeNewswire (Europe) | Q-linea AB (publ) today announces that Malin Svensson has been appointed Chief Financial Officer and Investor Relations manager. She will assume her position no later than January 1, 2027
Malin Svensson... ► Artikel lesen | |
| 18.08. | Q-Linea AB: Q-linea awarded a contract position with Premier, Inc. | 876 | GlobeNewswire (Europe) | Q-linea AB (publ) has been awarded a contract position with national group purchasing organization, Premier, Inc.
Effective September 1, 2026, the new agreement allows the over 4,000 Premier member... ► Artikel lesen | |
| 10.08. | Q-Linea AB: Q-linea Announces ASTar Contract With Large Health System in the U.S. Mid-Atlantic Region | 496 | GlobeNewswire (Europe) | Q-linea AB (publ) announces today that it has signed a contract with a major U.S. health system in the mid-Atlantic region for deployment of its ASTar® rapid antimicrobial susceptibility testing (AST)... ► Artikel lesen | |
| 10.07. | Q-Linea AB: Interim report January 1 - June 30 2026 | 1.175 | GlobeNewswire (Europe) | FDA decision sets up for growth in U.S. FDA clearance for expanded U.S. menu combined with encouraging progress across Europe and focus organisation, positions Q-linea for growth during the second half... ► Artikel lesen | |
| 29.05. | Q-Linea AB: Annika Blondeau Henriksson new interim CFO | 507 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today announces that the company has hired Annika Blondeau Henriksson as CFO and IR. Annika takes office on June 15, 2026, when she succeeds Christer Samuelsson, who... ► Artikel lesen | |
| 27.05. | Q-linea AB: Bulletin From Annual General Meeting In Q-linea AB (publ) | 369 | GlobeNewswire (Europe) | The annual general meeting of Q-linea AB (publ) (the "Company"), reg. no. 556729-0217, was held on 27 May 2026 in Uppsala, at which the shareholders mainly passed the following resolutions. All resolutions... ► Artikel lesen | |
| 30.04. | Q-Linea AB: Interim report January - March 2026 | 439 | GlobeNewswire (Europe) | Growing recurring income and increased market activity within rapid AST
First quarter: 1 January-31 March 2026Income from sales of consumables amounted to SEK 1.4 (0.9) million, an increase of approx.... ► Artikel lesen | |
| 16.04. | Q-Linea AB: Q-linea announces FDA clearance of expanded ASTar blood testing menu | 628 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today announces the company has received 510(k) clearance from the US FDA for its expanded ASTar® Gram-negative Blood Culture menu.
The expanded panel represents a significant... ► Artikel lesen | |
| 30.12.25 | Q-Linea AB: Q-linea signs first distribution agreement in South Asia | 524 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA today announces the signing of its first distribution agreement in South Asia, marking an important milestone in the company's global expansion strategy. The agreement... ► Artikel lesen | |
| 23.12.25 | Q-Linea AB: Q-linea announces first two US hospital systems' clinical implementation of ASTar | 292 | GlobeNewswire (Europe) | Q-linea AB (Publ) (OMX: QLINEA) announces the clinical implementation of the first US ASTar instruments at UI (University of Iowa) Health Care and a large healthcare system in Texas. UI Health Care... ► Artikel lesen | |
| 20.11.25 | Q-Linea AB: Q-linea announces new organisation and changes in executive leadership team | 474 | GlobeNewswire (Europe) | Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) today announces that it has reached agreement with all relevant unions regarding the company's new organisation. As part of these changes, Ylva Molin has... ► Artikel lesen | |
| 18.11.25 | Q-Linea AB: Q-linea announces FDA submission for expanded claims for ASTar BC G- panel | 803 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today announces their FDA 510(k) submission for expanded organism and antimicrobial claims on their ASTar BC G- panel, improving the clinical utility of the panel for... ► Artikel lesen | |
| 11.11.25 | Q-Linea AB: Q-linea announces outcome of rights issue | 303 | GlobeNewswire (Europe) | Q-linea AB (publ) ("Q-linea" or the "Company") (Nasdaq Stockholm: QLINEA) announces the outcome of the Company's rights issue of approximately SEK 322 (the "Rights Issue"), for which the subscription... ► Artikel lesen | |
| 24.10.25 | Listing of subscription rights and paid subscription shares of Q-Linea AB | 439 | GlobeNewswire | With effect from October 27, 2025, the subscription rights of Q-Linea AB will be traded on the list for Equity rights. Trading will continue up until and including November 05, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 22.10.25 | Q-Linea AB: Q-linea announces cost efficiency program to accelerate sales and marketing activities | 333 | GlobeNewswire (Europe) | Driven by Q-linea's strong commercial progression with a growing customer base, Q-linea today announced a cost efficiency program to optimise the organisation and cost structure to meet the increasing... ► Artikel lesen | |
| 21.10.25 | Q-Linea AB: Bulletin from Extraordinary General Meeting in Q-Linea AB (publ) | 300 | GlobeNewswire (Europe) | The extraordinary general meeting of Q-linea AB (publ) (the "Company"), org.nr. 556729-0217, was held on October 21, 2025 in Uppsala, Sweden, at which the shareholders primarily resolved as follows.... ► Artikel lesen | |
| 21.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.10.2025 | 417 | Xetra Newsboard | Das Instrument 3F80 SE0025420714 Q-LINEA AB EQUITY wird cum Kapitalmassnahme gehandelt am 21.10.2025 und ex Kapitalmassnahme am 22.10.2025 The instrument 3F80 SE0025420714 Q-LINEA AB EQUITY is traded... ► Artikel lesen | |
| 20.10.25 | Q-Linea AB: Interim report 1 January - 30 September 2025 | 317 | GlobeNewswire (Europe) | Strong pipeline growth while the installed base of ASTar increases demand for consumables
The quarter July - September 2025Net sales amounted to SEK 3.5 (0.6) million.Operating result (EBIT) of SEK... ► Artikel lesen | |
| 19.10.25 | Q-Linea AB: Stuart Gander appointed CEO and Anders Ljunggren appointed deputy CEO of Q-linea AB | 319 | GlobeNewswire (Europe) | The board of directors of Q-linea AB (publ) has today appointed Stuart Gander as CEO of the company. Former CEO Anders Ljunggren continues as deputy CEO of the company.
Since March 1, 2024, Stuart Gander... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 42,485 | +2,15 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius vor einem Treffen mit dem Chef Michael Sen auf "Buy" mit einem Kursziel von 55 Euro belassen. Die geschäftliche... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,610 | +2,42 % | Fresenius Medical Care Aktie: Wechsel an der Konzernspitze | Fresenius Medical Care bekommt kurzfristig einen neuen Vorstandschef. Shervin J. Korangy übernimmt mit Wirkung zum 12. Oktober 2026 den Vorsitz des Vorstands. Der Aufsichtsrat hat die Personalie am... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,220 | +3,73 % | 200-Tage-Linie hält: Goldman verpasst Zeiss Meditec einen Dämpfer | Goldman Sachs stuft Carl Zeiss Meditec auf "Sell" ab und senkt das Kursziel auf 23 Euro. Zwischenzeitlich verlor das Papier gut sieben Prozent, fing sich dann aber knapp über der 200-Tage-Linie. Die... ► Artikel lesen | |
| INTUITIVE SURGICAL | 370,25 | -0,11 % | Intuitive Surgical: Bewertungsabschlag ohne Bruch der Investment-Story - Chance für geduldige Qualitätsanleger? | Intuitive Surgical bleibt operativ auf Kurs, während die Bewertung nachgibt. Trotz temporärer Belastungen durch Nachholeffekte aus der Pandemie und makroökonomische Unsicherheiten sieht Seeking Alpha... ► Artikel lesen | |
| DRAEGERWERK | 114,00 | +2,33 % | Draegerwerk AG & Co. KGaA: Sechsjähriger FDA-Belastungsfaktor beseitigt; US-Monitoring-Geschäft rückt wieder in den Fokus; KAUFEN | Dräger hat ein sechs Jahre währendes regulatorisches Kapitel im US-Patientenmonitoring endlich abgeschlossen. Nach der FDA-Freigabe (Clearance) von Dräger IACS VG8.1 hat die Behörde den 2020 ausgesprochenen... ► Artikel lesen | |
| MEDTRONIC | 77,80 | -0,56 % | Zwei Dividendenwerte im Crash-Rabatt: Warum Cisco und Medtronic jetzt ins Visier konservativer Anleger rücken | Der jüngste Kursrückgang an den Aktienmärkten eröffnet nach Einschätzung eines Beitrags auf Seeking Alpha selektive Einstiegsgelegenheiten bei dividendenstarken Blue Chips. Im Fokus stehen Cisco Systems... ► Artikel lesen | |
| THERMO FISHER | 579,80 | -0,24 % | Thermo Fisher Scientific: Strategische Neuausrichtung und Margenwachstum! | ||
| TELADOC HEALTH | 4,879 | -1,15 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| HIMS & HERS HEALTH | 25,380 | +1,44 % | Truist reiterates Hold on Hims and Hers stock, $32 target | ||
| M1 AESTHETICS | 12,700 | -3,79 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,070 | -4,88 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| ALCON | 56,96 | +1,75 % | 589 Millionen Menschen mit Diabetes: Warum die globale Diabetes-Welle zum Technologiethema für die Augen wird - und wo Rise Nano Optics ins Spiel kommt | ||
| DEXCOM | 75,00 | -0,53 % | Medtech-Branche: Citi bestätigt Abbott und Dexcom als Top-Picks | ||
| ADAPTHEALTH | 6,065 | 0,00 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,65 | 0,00 % | BMO Capital reiterates Outperform on BrightSpring Health stock |
Das Unternehmen Q-LINEA AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,455 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu Q-LINEA AB finden Sie auf Wallstreet Online.